Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis
Journal of Translational Medicine
Journal of Translational Medicine 2009, 7:29 doi:10.1186/1479-5876-7-29
Neil H Riordan1, Thomas E Ichim*1, Wei-Ping Min2, Hao Wang2, Fabio Solano3, Fabian Lara3, Miguel Alfaro4, Jorge Paz Rodriguez5,Robert J Harman6, Amit N Patel7, Michael P Murphy8, Roland R Lee9,10 and Boris Minev11,12
The stromal vascular fraction (SVF) of adipose tissue is known to contain mesenchymal stem cells (MSC), T regulatory cells, endothelial precursor cells, preadipocytes, as well as anti-inflammatory M2 macrophages. Safety of autologous adipose tissue implantation is supported by extensive use of this procedure in cosmetic surgery, as well as by ongoing studies using in vitro expanded adipose derived MSC. Equine and canine studies demonstrating anti-inflammatory and regenerative effects of non-expanded SVF cells have yielded promising results. Although non-expanded SVF cells have been used successfully in accelerating healing of Crohn’s fistulas, to our knowledge clinical use of these cells for systemic immune modulation has not been reported. In this communication we discuss the rationale for use of autologous SVF in treatment of multiple sclerosis and describe our experiences with three patients. Based on this rationale and initial experiences, we propose controlled trials of autologous SVF in various inflammatory conditions.
The patients treated were part of a compassionate-use evaluation of stem cell therapeutic protocols in a physician-initiated manner. Previous experiences in MS patients using allogeneic CD34+ cord blood cells together with MSC did not routinely result in substantial improvements observed in the three cases described above. While obviously no conclusions in terms of therapeutic efficacy can be drawn from the above reports, we believe that further clinical evaluation of autologous SVF cells is war- ranted in autoimmune conditions.